| Literature DB >> 34803921 |
Tian-Han Zhou1, Bei Lin1, Fan Wu1, Kai-Ning Lu2, Lin-Lin Mao2, Ling-Qian Zhao1, Ke-Cheng Jiang1, Yu Zhang2, Wei-Jun Zheng3, Ding-Cun Luo2.
Abstract
Purpose: To investigate the prognostic significance of extranodal extension (ENE) in papillary thyroid cancer (PTC).Entities:
Keywords: extranodal extension; lymph node metastasis; papillary thyroid carcinoma; prognosis; propensity score matching; the real world
Mesh:
Year: 2021 PMID: 34803921 PMCID: PMC8595930 DOI: 10.3389/fendo.2021.759049
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Process of patient enrollment into the study cohort and included patients. ENE, extranodal extension; PTC, papillary thyroid carcinoma.
Figure 2Anatomical diagram of extranodal extension in papillary thyroid cancer.
Baseline characteristics of the PTC patients.
| Variate | ENE (n = 34) | Non-ENE (n = 709) |
|
|---|---|---|---|
| Sex | |||
| Female | 21 | 502 | 0.259 |
| Male | 13 | 207 | |
| Age (years) | 47.94 ± 14.22 | 42.54 ± 12.59 | |
| <55 years | 23 | 575 | 0.015 |
| ≥55 years | 11 | 134 | |
| Size | 15.26 ± 10.84 | 10.51 ± 8.16 | |
| ≤1 cm | 12 | 466 | 0.001 |
| >1 cm | 22 | 243 | |
| Multifocality | |||
| Unifocal | 20 | 526 | 0.047 |
| Multifocal | 14 | 175 | |
| Extrathyroidal extension | |||
| No | 16 | 589 | <0.001 |
| Yes | 18 | 120 | |
| Hashimoto’s thyroiditis | |||
| No | 3 | 606 | 0.353 |
| Yes | 31 | 103 | |
| Nodal stage | |||
| N1a | 3 | 500 | <0.001 |
| N1b | 31 | 209 | |
| Distant metastasis | |||
| Yes | 2 | 0 | <0.001 |
| No | 32 | 709 | |
| Complications | |||
| No | 32 | 693 | 0.179 |
| Yes | 2 | 16 |
ENE, extranodal extension; PTC, papillary thyroid carcinoma.
Extranodal extension in the central and lateral neck compartments.
| Central neck compartment | Lateral neck compartment | ||
|---|---|---|---|
| Tumor size | 17.76 ± 13.66 mm | Tumor size | 15.27 ± 10.87 mm |
| Recurrent laryngeal nerve | 13 | Internal jugular vein | 13 |
| Adipose tissue | 4 | Adipose tissue | 9 |
| Parathyroid gland | 1 | Accessory nerve | 2 |
| Arteria carotis communis | 1 | ||
Logistic regression analysis of ENE-related risk factors.
| Variate | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Sex | 1.501 | 0.738~3.055 | 0.262 | 1.388 | 0.628~3.070 | 0.418 |
| Age | 1.033 | 1.006~1.062 | 0.017 | 1.036 | 1.006~1.066 | 0.016 |
| Multifocality | 2.012 | 0.996~4.065 | 0.051 | 11.894 | 0.875~4.100 | 0.105 |
| Hashimoto’s thyroiditis | 0.569 | 0.194~2.191 | 0.359 | 0.854 | 0.244~2.990 | 0.805 |
| Tumor size | 1.045 | 1.012~1.079 | 0.006 | 1.031 | 0.995~1.069 | 0.090 |
| Extrathyroidal extension | 5.522 | 2.738~11.136 | <0.001 | 2.958 | 1.399~6.256 | 0.005 |
| Nodal stage | 24.721 | 7.475~81.750 | <0.001 | 22.696 | 6.748~76.336 | <0.001 |
ENE, extranodal extension; OR, odds ratio.
Figure 3Comparison of recurrence-free survival of PTC patients before propensity score matching. ENE, extranodal extension; PTC, papillary thyroid carcinoma.
Baseline clinical characteristics and procedure characteristics after PSM.
| Variate | ENE (n = 26) | Non-ENE (n = 26) |
|
|---|---|---|---|
| Sex | |||
| Female | 18 | 20 | 0.532 |
| Male | 8 | 6 | |
| Age (years) | 44.08 ± 13.23 | 47.92 ± 13.40 | |
| <55 years | 20 | 14 | 0.303 |
| ≥55 years | 6 | 12 | |
| Size | 15.69 ± 11.74 | 14.92 ± 8.01 | |
| ≤1 cm | 6 | 8 | 0.784 |
| >1 cm | 20 | 18 | |
| Multifocality | |||
| Unifocal | 15 | 15 | 1.000 |
| Multifocal | 11 | 11 | |
| Extrathyroidal extension | |||
| Yes | 14 | 17 | 0.397 |
| No | 12 | 9 | |
| Hashimoto’s thyroiditis | |||
| Yes | 2 | 6 | 0.124 |
| No | 24 | 20 | |
| Nodal stage | |||
| N1a | 3 | 3 | 1.000 |
| N1b | 23 | 23 |
ENE, extranodal extension; PSM, propensity score matching.
Figure 4Comparison of recurrence-free survival of PTC patients after propensity score matching. ENE, extranodal extension; PTC, papillary thyroid carcinoma.
Cox regression analysis of patients before and after PSM.
| Variate | Before PSM | After PSM | ||
|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| |
| Age | 1.041 (1.010~1.073) | 0.009 | 1.060 (0.973~1.154) | 0.182 |
| Size | 1.040 (1.005~1.076) | 0.026 | 1.082 (1.029~1.139) | 0.002 |
| ENE | 3.600 (1.378~9.405) | 0.009 | 7.178 (1.191~43.249) | 0.031 |
ENE, extranodal extension; HR, hazard ratio; PSM, propensity score matching.